💊
Respreeza
alpha1-proteinase inhibitor (human)
Doenças Genéticas, Congênitas; Doenças Pulmonares
✅ Autorizado
✅
Nenhum alerta ativo
Este medicamento não apresenta escassez contínua, cartas de segurança ou recolhimentos.
Para que serve
Respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.
⚠️ Segurança do paciente
No
📚 Alertas anteriores (4)
Página oficial da EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza